CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway
- PMID: 36951936
- DOI: 10.1007/s12010-023-04436-7
CDK12 Promotes the Proliferation, Migration, and Angiogenesis of Gastric Carcinoma via Activating the PI3K/AKT/mTOR Signaling Pathway
Abstract
Cyclin-dependent kinase 12 (CDK12) has been found to regulate tumor progression. However, its function in gastric carcinoma (GC) remains controversial. This work aimed to explore the exact effect of CDK12 on GC progression. We detected the expression of CDK12 in GC cells and normal gastric mucosal epithelial cells. Then CDK12 function on GC cell proliferation, migration, and angiogenesis was researched by colony formation experiment, Transwell experiment, and angiogenesis assay. Moreover, CDK12 effect on the PI3K/AKT/mTOR pathway activity was explored by western blot. Further, we used LY294002 (10 μM) to treat GC cells to verify whether CDK12 regulates GC progression by activating the PI3K/AKT/mTOR pathway. Additionally, CDK12 effect on the expression of prognostic factors of GC was detected by western blot, including alkaline phosphatase (ALP) and Ki67. Quantitative real-time polymerase chain reaction and western blot were utilized to evaluate the expression of mRNAs and proteins. As a result, CDK12 was upregulated in GC cells. CDK12 overexpression facilitated the proliferation, migration, and angiogenesis of GC cells. However, CDK12 silencing showed an opposite result. CDK12 overexpression activated the PI3K/AKT/mTOR pathway, but CDK12 silencing inactivated it in GC cells. The blockage of the PI3K/AKT/mTOR pathway induced by LY294002 treatment counteracted the promotion of CDK12 on the proliferation, migration, and angiogenesis of GC. Further, CDK12 silencing suppressed the expression of ALP and Ki67 proteins in GC cells. Taken together, CDK12 promotes the proliferation, migration, and angiogenesis of GC by activating the PI3K/AKT/mTOR pathway. It may be a novel target for GC treatment.
Keywords: Angiogenesis; CDK12; GC; Migration; PI3K/AKT/mTOR; Proliferation.
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Similar articles
-
Inhibition of PI3K/Akt/mTOR Signaling Pathway Suppresses 5-Fluorouracil Resistance in Gastric Cancer.Mol Biotechnol. 2024 Dec;66(12):3640-3654. doi: 10.1007/s12033-023-00966-x. Epub 2023 Nov 24. Mol Biotechnol. 2024. PMID: 37999920
-
CYP2E1 changes the biological function of gastric cancer cells via the PI3K/Akt/mTOR signaling pathway.Mol Med Rep. 2020 Feb;21(2):842-850. doi: 10.3892/mmr.2019.10890. Epub 2019 Dec 17. Mol Med Rep. 2020. PMID: 31974627 Free PMC article.
-
Circular RNA hsa_circ_0010882 promotes the progression of gastric cancer via regulation of the PI3K/Akt/mTOR signaling pathway.Eur Rev Med Pharmacol Sci. 2020 Feb;24(3):1142-1151. doi: 10.26355/eurrev_202002_20165. Eur Rev Med Pharmacol Sci. 2020. PMID: 32096170
-
Signaling Activation and Modulation in Extrafollicular B Cell Responses.Immunol Rev. 2025 Mar;330(1):e70004. doi: 10.1111/imr.70004. Immunol Rev. 2025. PMID: 39917832 Free PMC article. Review.
-
Research progress of anticancer drugs targeting CDK12.RSC Med Chem. 2023 May 23;14(9):1629-1644. doi: 10.1039/d3md00004d. eCollection 2023 Sep 19. RSC Med Chem. 2023. PMID: 37731700 Free PMC article. Review.
Cited by
-
New insights into the dule roles CDK12 in human cancers: Mechanisms and interventions for cancer therapy.J Pharm Anal. 2025 Jul;15(7):101173. doi: 10.1016/j.jpha.2024.101173. Epub 2024 Dec 28. J Pharm Anal. 2025. PMID: 40747342 Free PMC article. Review.
-
Branched-chain amino acid and cancer: metabolism, immune microenvironment and therapeutic targets.J Transl Med. 2025 Jun 10;23(1):636. doi: 10.1186/s12967-025-06664-3. J Transl Med. 2025. PMID: 40495192 Free PMC article. Review.
-
Cyclin-dependent kinases as mediators of aberrant transcription in prostate cancer.Transl Oncol. 2025 May;55:102378. doi: 10.1016/j.tranon.2025.102378. Epub 2025 Mar 30. Transl Oncol. 2025. PMID: 40163908 Free PMC article. Review.
-
CDK12 inhibition enhances oxaliplatin efficacy in gastric cancer by suppressing the MAPK signaling pathway.J Gastrointest Oncol. 2025 Jun 30;16(3):823-839. doi: 10.21037/jgo-2025-392. Epub 2025 Jun 23. J Gastrointest Oncol. 2025. PMID: 40672076 Free PMC article.
References
-
- Joshi, S. S., & Badgwell, B. D. (2021). Current treatment and recent progress in gastric cancer., 71(3), 264–279.
-
- Ma, H.F. and P. Shu, (2022) Identification of miR 4510 as a metastasis suppressor of gastric cancer through regulation of tumor microenvironment via targeting GPC3 39 2 363-374
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous